Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

3(12%)

Phase Distribution

Ph phase_2

68%

Ph phase_1

20%

Ph phase_3

Ph not_applicable

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution25 total trials

Phase 1Safety & dosage

5(20.0%)

Phase 2Efficacy & side effects

17(68.0%)

Phase 3Large-scale testing

2(8.0%)

N/ANon-phased studies

1(4.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

10.5%

2 of 19 finished

Non-Completion Rate

89.5%

17 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(17)

Other(6)

Detailed Status

Withdrawn14

unknown5

Terminated3

Completed2

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (20.0%)

Phase 217 (68.0%)

Phase 32 (8.0%)

N/A1 (4.0%)

Trials by Status

unknown520%

completed28%

suspended14%

terminated312%

withdrawn1456%

Recent Activity

0 active trials

Showing 5 of 25

completednot_applicable

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819

withdrawnphase_2

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00101140

withdrawnphase_2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

NCT00310128

withdrawnphase_2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773

withdrawnphase_2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

NCT00253526

View all 25 trials

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more

NCT01872819Not Applicable

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Completed

NCT00101140Phase 2

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn

NCT00310128Phase 2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Withdrawn

NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn

NCT00253526Phase 2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn

NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended

NCT00072540Phase 2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Withdrawn

NCT00002482Phase 1

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Unknown

NCT00003517Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Withdrawn

NCT00003486Phase 2

Antineoplaston Therapy in Treating Patients With Colon Cancer

Withdrawn

NCT00003514Phase 2

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Withdrawn

NCT00003502Phase 2

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Withdrawn

NCT00003455Phase 2

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Withdrawn

NCT00003505Phase 2

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Withdrawn

NCT00112879Phase 2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn

NCT00003536Phase 2

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

Withdrawn

NCT00427570Phase 3

Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery

Completed

NCT00066417Phase 2

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated

NCT00025051Phase 2

Celecoxib in Preventing Skin Cancer

Withdrawn

NCT00098917Phase 1

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Terminated

Drug Details

Intervention Type: PROCEDURE
Total Trials: 25